Skip to main content

Table 1 Summary of studies included in the meta-analysis

From: Perioperative blood transfusion adversely affects prognosis after resection of lung cancer: a systematic review and a meta-analysis

Reference (Year)

EI (Country)

FD (MM) (No. of lost)

Group

No. of patients (M/F)

Age, years

PHB, g/dl

Pathology Aa/Sc/Lc/Ot

TS I/II/II/IV

OT Pr/Pn

Quality score

Tartter [2] (1984)

1966–1980 (USA)

24

Transfused

92 (−)

–

–

–

All stage I

–

4

(−)

Non-transfused

73 (−)

–

–

–

All stage I

–

Hyman [3] (1985)

1971–1979 (USA)

–

Transfused

33 (25/8)

59.5 ± 8

–

9/21/3/0

27/6/0/0

22/11

5

(−)

Non-transfused

72 (58/14)

62.4 ± 7.1

–

20/38/11/3

67/5/0/0

55/17

Pastorino [6] (1986)

1974–1979 (Italy)

–

Transfused

157 (147/10)

> 60, n = 75

–

53/79/25/0

All stage I

113/44

6

(−)

Non-transfused

126 (117/9)

> 60, n = 64

–

49/59/18

All stage I

105/21

Keller [7] (1988)

1974–1981 (USA)

(−)

Transfused

144 (91/53)

≥ 65.1, n = 73

–

–

119/25/0/0

127/17

5

–

Non-transfused

208 (149/59)

≥ 65.1, n = 65

–

–

186/22/0/0

201/7

Little [5] (1990)

1977–1986 (USA)

47

Transfused

58 (32/26)

61.3 ± 8.8

–

26/25/7/0

All stage I

48/10

5

(0)

Non-transfused

59 (28/31)

60.1 ± 9.6

–

37/16/6/0

All stage I

51/8

Pena [8] (1992)

1980–1984 (USA)

–

Transfused

30 (24/6)

66.1 ± 7.6

12.8 ± 1.9

10/15/3/2

23/7/0/0

22/8

6

(−)

Non-transfused

97 (78/19)

62.0 ± 8.0

14.2 ± 1.3

41/41/12/3

75/22/0/0

71/26

Piantadosi [13] (1994)

1974–1981 (USA)

43.2

Transfused

169 (−)

–

–

–

–

–

6

(−)

Non-transfused

161 (−)

–

–

–

–

–

Rainio [9] (1996)

1978–1980 (Finland)

–

Transfused

95 (88/7)

–

–

–

60/8/27/0

–

5

(−)

Non-transfused

113 (102/11)

–

–

–

83/10/20

–

Nosotti [14] (2003)

1995–2000 (Italy)

34

Transfused

69 (52/17)

65.6 ± 9.4

12.5 ± 1.2

39/28/2/0

All stage I

–

6

(38)

Non-transfused

212 (153/59)

64.5 ± 9.5

13.3 ± 3.1

139/66/7/0

All stage I

–

Rzyman [15] (2003)

1993–1997 (Poland)

46

Transfused

185 (155/30)

59.5

≤12, 25%

51/113/19/2

62/41/80/2

113/72

4

(0)

Non-transfused

163 (125/38)

60.3

≤12, 12%

43/108/9/3

85/33/41/4

121/42

Ghosh [16] (2004)

1996–2003 (UK)

23.2#

Transfused

120 (73/47)

72

–

62/58/0/0

29/66/27/0

All Pr

5

(−)

Non-transfused

209 (99/110)

69

–

83/126/0/0

53/85/58/0

All Pr

Berardi [17] (2005)

1996–2001 (Italy)

27

Transfused

97 (−)

–

–

–

–

–

4

(−)

Non-transfused

342 (−)

–

–

–

–

–

Peñalver [18] (2005)

1969-2000 (Spain)

208.6#

Transfused

125 (120/5)

62.6 ± 9.01

–

21/89/15/0

All stage I

81/44

5

(−)

Non-transfused

731 (688/43)

61.9 ± 8.95

–

199/466/66/0

All stage I

584/147

Chen [19] (2007)

1993-2002 (China)

–

Transfused

135 (110/25)

58.6 ± 11.2

13.8 ± 2.1

60/55/5/15

50/27/58/0

–

5

(0)

Non-transfused

145 (117/28)

59.8 ± 11.1

14.2 ± 1.4

75/52/5/13

74/26/45/0

–

Thomas [20] (2007)

1993–2002 (France)

–

Transfused

139 (−)

–

–

39/77/17/6

–

All Pn

5

–

Non-transfused

228 (−)

–

–

70/113/25/20

–

All Pn

Panagopoulos [21] (2008)

1999–2005 (Greece)

27.2

Transfused

85 (74/11)

64 ± 9

11.5 ± 1.6

30/46/7/2

33/27/23/2

45/40

4

(0)

Non-transfused

246 (221/25)

64 ± 9

12.7 ± 1.3

85/132/24/5

115/65/61/5

164/82

Ng [22] (2012)

2001–2009 (USA)

48

Transfused

63 (31/32)

74

12.6

43/12/6/2

All stage I

All Pr

6

(0)

Non-transfused

298 (130/168)

67

13.5

187/69/21/21

All stage I

All Pr

Cata [23] (2013)

2004–2006 (USA)

63.6

Transfused

60 (31/29)

66.2 ± 9.4

12.08 ± 1.58

–

23/16/21/0

–

6

37

Non-transfused

576 (267/309)

65.1 ± 10.5

13.43 ± 1.42

–

328/115/131/0

–

  1. EI Enrolment interval; UK United Kingdom; FD Follow-up duration; MM Median months; M Male; F Female; PHB Preoperative hemoglobin; TS Tumor stage; Aa Adenocarcinoma; Sc Squamous cell carcinoma; Lc Large cell carcinoma; Ot Other types; OT Operation type; Pr Partial resection (segmentectomy; lobectomy; bilobectomy); Pn Pneumonectomy.
  2. #Mean.